12:51 , Jun 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Depression Analysis of a patient adverse event database and mouse studies suggest promoting the expression of HspH1 could help treat depression. In the FDA Adverse Event Reporting System (FAERS) database, the incidence of depression was...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Qiagen, French National Institute of Health and Medical Research (Inserm) deal

Inserm and its Inserm Transfert S.A. subsidiary granted Qiagen's Qiagen Marseille subsidiary worldwide rights to IP around mutations in the heat shock 105 kDa protein 1 ( HspH1; Hsp105; Hsp110). Qiagen said detection...
07:00 , Oct 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer (CRC) Heat shock 105 kDa protein 1 (HSPH1; HSP105; HSP110) Studies in patient samples and...
07:00 , Sep 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-Hodgkin's lymphoma (NHL) Heat shock 105 kDa/110 kDa protein 1 (HSPH1; HSP105) Studies in mice...